The drug most commonly associated with being pulled from the market and returning multiple times is phenylpropanolamine, or PPA, a stimulant compound that saw use as both a nasal decongestant and appetite suppressant across several decades. PPA’s regulatory history is one of the more unusual stories in pharmaceutical oversight — it was flagged for safety concerns, removed from over-the-counter products, and in some formulations or markets reappeared, only to face renewed scrutiny. For anyone caring for a loved one with dementia or cognitive decline, PPA’s story matters because it was once found in dozens of common cold and diet medications that older adults may have taken routinely, and its association with hemorrhagic stroke has direct relevance to brain health. This pattern of market withdrawal and return is not unique to PPA, but PPA is the most prominent example where the cycle repeated itself in ways that left consumers confused and, in some cases, harmed.
Other drugs like rofecoxib (Vioxx) and valdecoxib (Bextra) were pulled and never came back, while some medications have been withdrawn in certain countries but remained available in others. PPA occupies a strange middle ground — regulatory agencies in different nations acted at different times, and reformulated products sometimes slipped back into circulation before being pulled again. This article will walk through PPA’s full history, explain why it kept returning, explore the brain health risks it poses, and discuss what caregivers and older adults should know about medications with troubled regulatory histories. Beyond PPA itself, this piece covers the broader FDA withdrawal process, how drugs end up back on shelves after safety concerns, and what questions you should be asking your pharmacist if you or someone you care for is taking a medication with a checkered past.
Table of Contents
- Why Was Phenylpropanolamine Pulled from the Market Multiple Times?
- What Are the Brain Health Risks of Drugs That Get Pulled and Reintroduced?
- How the FDA Drug Withdrawal Process Actually Works
- What Caregivers Should Do When a Medication Has a Troubled History
- The Problem of Old Medications in the Homes of People with Dementia
- International Differences in Drug Availability and What That Means for Families
- What PPA’s Story Tells Us About the Future of Drug Safety
- Conclusion
- Frequently Asked Questions
Why Was Phenylpropanolamine Pulled from the Market Multiple Times?
Phenylpropanolamine first came under serious regulatory scrutiny in the 1980s when reports began linking it to elevated blood pressure and, more alarmingly, to hemorrhagic stroke — a type of bleeding in the brain. The compound had been used since the 1940s in various cold remedies and weight-loss pills, and by the 1970s it was one of the most widely consumed over-the-counter ingredients in the United States. Early concerns led to advisory panels recommending restrictions, and some formulations were quietly pulled. However, the ingredient persisted in many products because manufacturers reformulated or reduced dosages, arguing that lower amounts were safe. This created a cycle: concern, partial withdrawal, reformulation, return. The most decisive action came in November 2000, when the FDA issued a public health advisory requesting that manufacturers voluntarily remove PPA from all drug products. This followed the publication of the Hemorrhagic Stroke Project, a study conducted at Yale University that found an association between PPA use and hemorrhagic stroke, particularly in women.
Products like Dexatrim (a popular diet pill) and Triaminic (a children’s cold medicine) were among those reformulated to remove PPA. However, PPA did not disappear globally. In some countries, PPA-containing products remained available for years after the FDA advisory, and in certain markets, products containing PPA returned to shelves after temporary removals when local regulators reached different conclusions or when enforcement was lax. The comparison to a drug like Vioxx is instructive. Vioxx was pulled once, decisively, in 2004 after being linked to heart attacks and strokes, and it never came back. PPA’s saga was messier because it was an ingredient in many products made by many manufacturers, and because the evidence accumulated gradually rather than arriving all at once in a single damning study. This fragmented regulatory response is a significant reason PPA kept returning.
What Are the Brain Health Risks of Drugs That Get Pulled and Reintroduced?
The central brain health risk associated with PPA is hemorrhagic stroke — bleeding within the brain tissue or in the space surrounding the brain. For someone already living with dementia or mild cognitive impairment, a hemorrhagic event can be devastating, accelerating cognitive decline and potentially causing death. The Yale-led Hemorrhagic Stroke Project estimated that PPA use, particularly at higher doses found in appetite suppressants, was associated with a significantly elevated risk of this type of stroke in women within the first three days of use. While the absolute risk for any individual was relatively small, the sheer number of people taking PPA-containing products meant that the population-level impact was substantial. However, the brain health risks extend beyond PPA itself.
When any drug is pulled from the market and later returns — whether in a different formulation, a different market, or under a different brand name — there is a period of confusion during which consumers and even healthcare providers may not realize they are taking or prescribing a substance with a known safety history. For older adults with dementia, who may be taking multiple medications and who may not be able to advocate for themselves in a pharmacy setting, this is particularly dangerous. A caregiver who remembers that “Dexatrim was fine, I took it in the 90s” might not realize the original formulation contained PPA, or might encounter a foreign-market product that still contains it. It is worth noting a limitation here: the hemorrhagic stroke risk associated with PPA was most clearly established for higher doses and for certain populations. Lower-dose nasal decongestant formulations may have carried less risk, though the FDA ultimately concluded that no dose was worth the danger given the availability of safer alternatives like pseudoephedrine and phenylephrine. If you are caring for someone with dementia and you find old medications in their home — something that happens frequently when families begin providing care — check the ingredient list for phenylpropanolamine and dispose of any product containing it.
How the FDA Drug Withdrawal Process Actually Works
The FDA does not pull drugs from the market lightly, and the process is often slower than the public expects. In most cases, the agency first issues safety communications or requires updated warning labels. If the evidence grows more serious, the FDA may convene an advisory committee of outside experts to review the data. Only after this process does the agency typically request a voluntary withdrawal or, in rare cases, mandate a recall. With PPA, this process played out over roughly two decades, from early safety signals in the 1980s to the formal advisory in 2000.
One specific example that illustrates the complexity: in 1983, an FDA advisory panel reviewed PPA and concluded it was “generally recognized as safe and effective” for use as a nasal decongestant at recommended doses, while expressing more concern about its use in diet pills at higher doses. This split decision meant that PPA remained in cold medications largely unchallenged for another seventeen years, even as case reports of strokes continued to accumulate. The pharmaceutical industry’s practice of self-regulation through voluntary compliance — rather than mandatory FDA enforcement — also meant that even after the 2000 advisory, some PPA-containing products lingered on pharmacy shelves for months. For caregivers and families dealing with dementia, the practical takeaway is sobering: just because a drug is currently on the market does not mean it is definitively safe, and just because a drug was pulled does not mean every product containing it disappeared immediately. Regulatory processes have built-in delays, and global markets do not move in lockstep. This is why periodic medication reviews with a pharmacist or physician are not optional — they are essential, especially for people with cognitive impairment who may not notice or report side effects.
What Caregivers Should Do When a Medication Has a Troubled History
If you discover that someone in your care is taking a medication that has been subject to market withdrawals, safety advisories, or significant label changes, the first step is not to panic and not to abruptly stop the medication. Abrupt discontinuation of some drugs can cause withdrawal effects or rebound symptoms that are worse than the original condition. Instead, contact the prescribing physician or a pharmacist and ask specifically: “Has this medication been subject to any FDA safety communications, and are there safer alternatives?” The tradeoff that often comes into play is between a medication’s known benefits and its known risks. For example, after PPA was removed from cold medications, many manufacturers switched to phenylephrine — which the FDA later determined, in 2023, to be ineffective as an oral decongestant.
This left pseudoephedrine as the primary effective over-the-counter decongestant, but pseudoephedrine carries its own risks for older adults, including elevated blood pressure and potential interactions with dementia medications like cholinesterase inhibitors. There is no perfect answer here, only a series of informed tradeoffs that should be made in consultation with a healthcare provider who knows the patient’s full medical history. For practical purposes, caregivers should maintain a current, written medication list — including over-the-counter products, supplements, and any foreign-purchased medications — and bring it to every medical appointment. The FDA’s MedWatch program allows anyone to report adverse drug events and to search for safety alerts on specific products. Historically, this has been one of the more reliable ways to stay informed about medications with evolving safety profiles.
The Problem of Old Medications in the Homes of People with Dementia
One issue that geriatric care specialists encounter regularly is the discovery of expired or recalled medications in the homes of older adults, particularly those with dementia. Cognitive decline often means that medication cabinets go unchecked for years. Family members stepping into caregiving roles frequently find bottles of drugs that were pulled from the market long ago, alongside current prescriptions, supplements of questionable origin, and medications prescribed to a now-deceased spouse. This is not a hypothetical concern. PPA-containing products were sold under dozens of brand names, and some of those products had long shelf lives.
A bottle of Dexatrim purchased in 1999 could theoretically still be sitting in a medicine cabinet today, and a person with dementia might take it without understanding that it has been recalled. The broader warning here applies to all medications, not just PPA: if you are beginning to provide care for someone with cognitive impairment, one of your first tasks should be a thorough medication inventory. Remove anything expired, anything you cannot identify, and anything that is not on the person’s current prescription or recommended OTC list. Bring the questionable items to a pharmacist rather than simply throwing them away, as pharmacies can often identify unlabeled pills and advise on proper disposal. A related limitation to be aware of: online medication databases and drug identification tools are useful but not infallible, especially for older products that may no longer appear in current databases. If you encounter a medication you cannot identify, a pharmacist remains the best resource.
International Differences in Drug Availability and What That Means for Families
PPA’s history highlights a reality that catches many families off guard: a drug that has been banned or withdrawn in one country may still be freely available in another. As of recent reports, PPA-containing products have remained available in parts of Asia and other regions long after the FDA’s 2000 advisory. For families with members who travel internationally, who purchase medications abroad, or who receive medications mailed from other countries, this creates a genuine safety gap.
A specific example: in some Southeast Asian countries, PPA has historically remained available in common cold preparations sold without prescription. An older adult with dementia whose family member brings back cold medicine from a trip abroad could unknowingly be exposed to a substance that was deemed too dangerous for the American market over two decades ago. This is not a criticism of other countries’ regulatory systems — different nations weigh evidence differently and have different risk tolerances — but it is a practical concern that caregivers need to be aware of, especially in multicultural families where medications may cross borders regularly.
What PPA’s Story Tells Us About the Future of Drug Safety
PPA’s repeated market withdrawals and returns are, in many ways, a product of an older regulatory era when post-market surveillance was less rigorous and when the burden of proof for removing a drug was higher than the burden for approving it. The FDA’s systems have improved substantially since 2000, with better adverse event reporting, more robust post-market studies, and faster communication channels. The agency’s Sentinel System, launched in 2008, now monitors data from hundreds of millions of insurance claims to detect safety signals in near real-time. Still, the fundamental tension remains: drugs are approved based on clinical trials involving thousands of patients observed for months or a few years, then released into a population of millions who take them for decades.
Some risks only become apparent at that scale and over that timeframe. For brain health specifically, this is a critical concern because many neurological harms — subtle cognitive decline, increased stroke risk, cumulative vascular damage — may not manifest immediately or obviously. The lesson of PPA is not that the system failed completely, but that it moved slowly, and that the people most vulnerable to its failures were those least able to protect themselves: older adults, people with existing cognitive impairment, and those without strong advocates in their healthcare. Being an informed, persistent advocate for your loved one’s medication safety is not paranoia. Given the history, it is simply good caregiving.
Conclusion
Phenylpropanolamine’s decades-long journey through market withdrawals and returns stands as one of the more instructive cautionary tales in pharmaceutical regulation. A drug that was once found in dozens of common cold and diet products was eventually linked to hemorrhagic stroke and removed from the American market, but not before a prolonged period of partial measures, reformulations, and mixed signals from regulators. For anyone involved in dementia care or concerned about brain health, PPA’s story is a concrete reminder that over-the-counter does not mean risk-free, and that regulatory action can lag behind emerging evidence by years or even decades.
The practical steps for caregivers are clear: conduct regular medication inventories, maintain an updated medication list, use the FDA’s MedWatch system to check for safety alerts, and never hesitate to ask a pharmacist or physician whether a specific product has a history of safety concerns. Be especially vigilant with medications purchased abroad or found in the homes of older adults who may have been self-medicating for years. Drug safety is not a settled question for any medication — it is an ongoing process, and the people who benefit most from that process are those who have someone paying attention on their behalf.
Frequently Asked Questions
Is phenylpropanolamine still available anywhere?
As of recent reports, PPA has been removed from over-the-counter products in the United States and many other countries following the FDA’s 2000 advisory. However, it has historically remained available in some international markets, particularly in parts of Asia. If you encounter a cold or diet medication purchased abroad, check the ingredient list carefully.
What replaced PPA in cold medications?
Most manufacturers switched to phenylephrine or pseudoephedrine after PPA was withdrawn. Notably, the FDA determined in 2023 that oral phenylephrine is not effective as a decongestant, leaving pseudoephedrine as the primary effective OTC option — though it requires purchase from behind the pharmacy counter in the United States and carries its own risks for older adults.
Can a single dose of PPA cause a stroke?
The Yale Hemorrhagic Stroke Project found an elevated risk of hemorrhagic stroke associated with PPA use, particularly within the first three days of use and at higher doses found in appetite suppressants. While a single dose is unlikely to cause harm in most people, the risk was considered significant enough at a population level for the FDA to recommend complete removal from the market.
How do I check if an old medication contains PPA?
Look at the active ingredients list on the product label for “phenylpropanolamine” or “phenylpropanolamine hydrochloride.” If you cannot read the label or the product is unlabeled, bring it to a pharmacist for identification. Do not take or administer any medication you cannot positively identify.
Should I be worried about other drugs being pulled and returning?
The PPA pattern of repeated withdrawal and return is relatively uncommon in modern pharmaceutical regulation. FDA post-market surveillance has improved significantly since 2000. However, it is always wise to stay informed about the medications you or your loved ones take. The FDA’s MedWatch program and your pharmacist are your best ongoing resources.
